USPTO serial 98498394
CLOUDBREAK FS
Reviewed by CopyMark Law Group
Status 731Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- THOMA, GABRIELLE M
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with CLOUDBREAK FS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,545*
Plus Government fees of $750
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Samantha C. Markley
Samantha C. Markley LOZA & LOZA, LLP305 N. Second Ave., #127Upland, CA 91786United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Assays and reagents for use in genetic research; diagnostic reagents for scientific or research use; diagnostic reagents for clinical or medical laboratory use, other than for medical or veterinary purposes; reagents and reagent kits, other than for medical or veterinary purposes, comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for scientific research use, for diagnostic scientific use, and for clinical laboratory research use; clinical diagnostic reagents for laboratory use, other than for medical or veterinary purposes; reagent kits and reagent beads, other than for medical or veterinary purposes, with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical diagnostic laboratory purposes; all of the foregoing for use in connection with genetic, genomic and multi-omic sequencing and/or research, and none of the foregoing for use in the fields of diabetes management, diabetes analyte testing, diabetes monitoring, glucose testing, glucose monitoring, ketone testing, and/or ketone monitoring | ACTIVE | — |
| 005 | Medical diagnostic reagents; clinical medical diagnostic reagents; reagent kits and reagent beads with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical medical diagnostic purposes; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for diagnostic medical use and for clinical medical use; diagnostic reagents for clinical or medical laboratory use, for medical or veterinary purposes; reagents and reagent kits, for medical or veterinary purposes, comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for clinical laboratory research use; clinical diagnostic reagents for laboratory use, for medical or veterinary purposes; reagent kits and reagent beads, for medical or veterinary purposes, with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical diagnostic laboratory purposes; all of the foregoing for use in connection with genetic, genomic and multi-omic sequencing and/or research, and none of the foregoing for use in the fields of diabetes management, diabetes analyte testing, diabetes monitoring, glucose testing, glucose monitoring, ketone testing, and/or ketone monitoring | ACTIVE | — |
| 009 | Computer systems, namely, computer hardware, downloadable and recorded computer software and associated downloadable data files for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, all the foregoing for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; downloadable and recorded computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; clinical diagnostic instruments for scientific use, namely, nucleic acid sequencers, imaging devices for nucleic acids and biological molecules and analyzers in the nature of scientific laboratory research instruments for DNA analysis; all of the foregoing for use in connection with genetic, genomic and multi-omic sequencing and/or research, and none of the foregoing for use in the fields of diabetes management, diabetes analyte testing, diabetes monitoring, glucose testing, glucose monitoring, ketone testing, and/or ketone monitoring | ACTIVE | — |
| 010 | Clinical diagnostic instruments for medical use, namely, nucleic acid sequencers, imaging devices for biomolecules and analyzers in the nature of flow-based analyzers providing cell and particle analysis, detection, or counting; all of the foregoing for use in connection with genetic, genomic and multi-omic sequencing and/or research, and none of the foregoing for use in the fields of diabetes management, diabetes analyte testing, diabetes monitoring, glucose testing, glucose monitoring, ketone testing, and/or ketone monitoring | ACTIVE | — |
| 042 | Providing reagent sample diagnostic testing services for others for scientific research purposes and scientific research related thereto; clinical diagnostic services for scientific research purposes, namely, preparing, amplifying, labeling, detecting, analyzing and sequencing nucleic acids from human beings; providing online non-downloadable computer software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, all the foregoing for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; providing online nondownloadable computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; all of the foregoing for use in connection with genetic, genomic and multi-omic sequencing and/or research, and none of the foregoing for use in the fields of diabetes management, diabetes analyte testing, diabetes monitoring, glucose testing, glucose monitoring, ketone testing, and/or ketone monitoring | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Element Biosciences, Inc.
- Other trademarks owned by Element Biosciences, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named CLOUDBREAK FS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 18, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 15, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 15, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 15, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 10, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 9, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 9, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 9, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 16, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 7, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jul 30, 2025 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Jul 30, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| Jun 6, 2025 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Feb 24, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 28, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 28, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 22, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 6, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 24, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 23, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 23, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 31, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 25, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 12, 2024 | NWAP | NEW APPLICATION ENTERED | — |